With the increasing scrutiny on drug safety and efficacy, understanding impurities is more important than ever and ever evolving guidelines are not aiding the efforts. To address those lacunas, Eminence has come up with 3rd Annual Pharma Impurity Conclave 2025 a virtual session, before we plan R&D and QC gathering in September. This training will cover a comprehensive range of topics, including the types of impurities, their sources, and the implications for product quality. Attendees can expect in-depth discussions on identifying genotoxic impurities, the role of raw materials, and the latest regulatory guidelines.
Additionally, sessions will focus on effective documentation practices for analytical R&D and Quality Control professionals, providing practical insights to enhance compliance and data integrity.
The program would focus on the daunting problem of nitrosamine, but also cover genotoxic impurities, assess product quality, elemental impurities and impurities caused by residual solvents, liposomes and complex molecules. The involvement of AI for organizing data and predicting impurity values during formulation would help in reducing drug recalls. We will also go through case studies to learn, unlearn and relearn about drug regulations.
Beside learning, a 6-month support for continuous learning would be provided so that all the stakeholders continue to safeguard the health of patients and protect the integrity of the pharmaceutical industry.
, CDSCO.jpg)
